Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: A double-blind, placebo-controlled study

Journal of Psychopharmacology

Volumn 26, Issue 11, 2012, Pages 1456-1462

  Bruno, Antonio ^a   Micò, Umberto ^a   Pandolfo, Gianluca ^a   Mallamace, Domenico ^a   Abenavoli, Elisabetta ^a   Di Nardo, Floriana ^a   D'Arrigo, Concetta ^b   Spina, Edoardo ^a,b   Zoccali, Rocco A ^a   Muscatello, Maria Rosaria A ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Cognitive functions; lamotrigine; obsessive compulsive disorder; serotonin reuptake inhibitors

Indexed keywords

LAMOTRIGINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY TEMPERATURE; BREATHING RATE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; HEADACHE; HEART RATE; HUMAN; MALE; MENTAL PERFORMANCE; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEDATION; SEIZURE; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; AGED; ANTICONVULSANTS; COGNITION; DOUBLE-BLIND METHOD; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME; TRIAZINES; YOUNG ADULT;

EID: 84867567407     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881111431751     Document Type: Article

References (57)

1. Aldenkamp AP, Baker G. A systematic review of the effects of lamotrigine on cognitive function and quality of life. Epilepsy Behav. 2001 ; 2: 85-91
2. Alkin T, Onur E, Ozerdem A. Co-occurrence of blepharospasm, tourettism and obsessive-compulsive symptoms during lamotrigine treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2007 ; 31: 1339-1340
3. Diagnostic and statistical manual of mental disorders. 2000 ) Diagnostic and statistical manual of mental disorders, (4th ed., text revision). Arlington, VA: American Psychiatric Association. Arlington, VA: American Psychiatric Association ; 2000 :
4. Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder. Arlington, VA: American Psychiatric Association ; 2007 :
5. Anand A, Charney DS, Oren DA, et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry. 2000 ; 57: 270-276
6. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2005 ; 19: 567-596
7. Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders-first revision. World J Biol Psychiatry. 2008 ; 9: 248-312
8. Bartels C, Wegrzyn M, Wiedl A, Ackermann V, Ehrenreich H. Practice effects in healthy adults: A longitudinal study on frequent repetitive cognitive testing. BMC Neurosci. 2010 ; 11: 118
9. Bloch MH, Landeros-Weisenberger A, Kelmendi B, et al. A systematic review: antipsychotic augmentation with treatment-refractory obsessive-compulsive disorder. Mol Psychiatr. 2006 ; 11: 622-632
10. Burstein AH. Lamotrigine. Pharmacotherapy. 1995 ; 15: 129-143
11. Calabrese JR, Sullivan JR, Bowden CL, Suppes T, Goldberg GF, Sachs GF. Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. J Clin Psychiatry. 2002 ; 63: 1012-1019
12. Chakrabarty K, Bhattacharyya S, Christopher R, Khanna S. Glutamatergic dysfunction in OCD. Neuropsychopharmacology. 2005 ; 30: 1735-1740
13. Chung SS, Kerls S, Hammer A, Kustra R. Cognitive effects of lamotrigine versus topiramate as adjunctive therapy in older adults with epilepsy. Neurol Int. 2009 ; 1: e6
14. Cora-Locatelli G, Greenberg BD, Martin J, Murphy DL. Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder [letter]. J Clin Psychiatry. 1998 ; 59: 480-481
15. Coric V, Taskiran S, Pittenger C, et al. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychol. 2005 ;: 424-428
16. D'Amico G, Cedro C, Muscatello MR, et al. Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2003 ; 27: 619-623
17. de Haan L, Beuk N, Hoogenboom B, et al. Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders. J Clin Psychiatry. 2002 ; 63: 104-107
18. Deltito JA. Valproate pretreatment for the difficult-to-treat patient with OCD [letter]. J Clin Psychiatry. 1994 ; 55: 500
19. Fineberg NA, Gale TM. Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int J Neuropsychopharmacol. 2005 ; 8: 107-129
20. Fineberg NA, Gale TM, Sivakumaran T. A review of antipsychotics in the treatment of obsessive compulsive disorder. J Psychopharmacol. 2006 ; 20: 97-103
21. Gao K, Muzina D, Gajwani P, et al. Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. J Clin Psychiatry. 2006 ; 67: 1327-1340
22. Goldberg TE, Goldman RS, Burdick KE, et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?. Arch Gen Psychiatry. 2007 ; 64: 1115-1122
23. Goodman WK. Obsessive-compulsive disorder: diagnosis and treatment. J Clin Psychiatry. 1999 ; 60: 27-32
24. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale Y-BOCS: part I. Development, use and reliability. Arch Gen Psychiatry. 1989a ; 46: 1006-1011
25. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale Y-BOCS: part II. Validity. Arch Gen Psychiatry. 1989b ; 46: 1012-1016
26. Goodwin G, Fleischhacker W, Arango C, et al. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. Eur Neuropsychopharmacol. 2009 ; 19: 520-532
27. Greenberg BD, Ziemann U, Corá-Locatelli G, et al. Altered cortical excitability in obsessive-compulsive disorder. Neurology. 2000 ; 54: 142-187
28. Guy W ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute for Mental Health 218-222. Revised DHEW Publication (ADM) ; 1976 :
29. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960 ; 23: 56-62
30. Heaton RK, Chelune GI, Talley JL, et al Wisconsin Card Sorting Test Manual: Revised and Expanded. Odessa, FL: Psychological Assessment Resources ; 1993 :
31. Hurley SC. Lamotrigine update and its use in mood disorders. Ann. Pharmacother. 2002 ; 36: 860-873
32. Iwata Y, Kotani Y, Hoshino R, et al. Carbamazepine augmentation of clomipramine in the treatment of refractory obsessive-compulsive disorder [letter]. J Clin Psychiatry. 2000 ; 61: 528-529
33. Kemp DE, Gilmer WS, Fleck J, Dago PL. An association of intrusive, repetitive phrases with lamotrigine treatment in bipolar II disorder. CNS Spectrums. 2007 ; 12: 106-111
34. Koran LM. Quality of life in obsessive compulsive disorder. Psychiatr Clin N Am. 2000 ; 23: 509-617
35. Kuloglu M, Caykoylu A, Ekinci O, Yilmaz E. Lamotrigine-induced obsessional symptoms in a patient with bipolar II disorder: a case report. J Psychopharmacol. 2008 ; 23: 1001-1003
36. Kumar TC, Khanna S. Lamotrigine augmentation of serotonin re-uptake inhibitors in obsessive-compulsive disorder. Aust NZ J Psychol. 2000 ; 34: 527-528
37. Labiner M. Lamotrigine and rash: scratching beneath the surface. J Clin Psychiatry. 2002 ; 63: 1010-1011
38. Lykouras L, Alevizos B, Michalopoulou P, Rabavilas A. Obsessive-compulsive symptoms induced by atypical antipsychotics: a review of the reported cases. Prog Neuropsychopharmacol Biol Psychiatry. 2003 ; 27: 333-346
39. McDougle CJ, Epperson CN, Pelton GH, et al. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry. 2000 ; 57: 794-801
40. McMeekin H. Successful treatment of obsessive-compulsive disorder with oxcarbazepine: a case report. J S C Med Assoc. 2003 ; 98: 316-320
41. March J, Frances A, Carpenter D, Kahn D. The export consensus guideline series. Treatment of obsessive-compulsive disorder. J Clin Psychiatry. 1997 ; 58: 1-64
42. Muscatello MR, Bruno A, Pandolfo G, et al. Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 2011 ; 31: 174-179
43. Pallanti S, Quercioli L. Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines. Prog Neuropsychopharmacol Biol Psychiatry. 2006 ; 30: 400-412
44. Pavuluri MN, Passarotti AM, Harral EM, Sweeney JA. Enhanced prefrontal function with pharmacotherapy on a response inhibition task in adolescent bipolar disorder. J Clin Psychiatry. 2010 ; 71: 1526-1534
45. Pittenger C, Krystal JH, Coric V. Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx. 2006 ; 3: 69-81
46. Poyurovsky M, Glick I, Koran LM. Lamotrigine augmentation in schizophrenia and schizoaffective patients with obsessive-compulsive symptoms. J Psychopharmacol. 2010 ; 24: 861-866
47. Prescribing information: Lamictal (lamotrigine) [online]. Available from URL: http://us.gsk.com/products/assets/ us-lamictal.pdf (accessed 15 January 2010).
48. Rosenberg DR, MacMaster FP, Keshavan MS, Fitzgerald KD, Stewart CM, Moore GJ. Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychol. 2000 ; 39: 1096-1103
49. Rosenberg DR, Mirza Y, Russell A, et al. Reduced anterior cingulated glutamatergic concentrations in childhood OCD and major depression versus healthy controls. J Am Acad Child Adolesc Psychol. 2004 ; 43: 1146-1153
50. Ross BD. Biochemical considerations in 1H spectroscopy: glutamate, glutamine, myoinositol and related products. NMR Biomed. 1991 ; 4: 59-63
51. Simon AB, Gorman JM. Advances in the treatment of anxiety: targeting glutamate. NeuroRx. 2006 ; 3: 57-68
52. Spitzer RL, Williams JBW, Gibbon M Structured Clinical Interview for DSM-IV (SCID). New York, NY: Biometric Research, New York State Psychiatric Institute ; 1995 :
53. Spreen O, Benton AL Neurosensory Center Comprehensive Examination For Aphasia (NCCEA). Victoria: University of Victoria Neuropsychology Laboratory ; 1977 :
54. Trenerry MR, Crosson B, DeBoe J, et al Stroop Neuropsychological Screening Test. Odessa, FL: Psychological Assessment Resources, Inc ; 1989 :
55. Uzun O. Lamotrigine as an augmentation agent in treatment-resistant obsessive-compulsive disorder: a case report. Psychopharmacology. 2010 ; 24: 425-427
56. Vulink NC, Denys D, Fluitman SB, et al. Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients. J Clin Psychiatry. 2009 ; 70: 1001-1008
57. Zohar J, Kindler S. Update of the serotonergic hypothesis of obsessive-compulsive disorder. Clin Neuropharmacol. 1992 ; 15: 257A - 258A